Topical Dermatologic Bioequivalence Methods May Vary According To Class
Executive Summary
Topical dermatological drug product bioequivalence methods may vary according to product classes, FDA Division of Dermatologic & Dental Drug Products Director Jonathan Wilkin, MD, told the Pharmaceutical Science Advisory Committee March 12
You may also be interested in...
Topical Bioequivalence For Unlike Emulsions Should Be Tested In Vivo – FDA
Bioequivalence of topical dermatologic drugs in different emulsions that target the stratum corneum should be determined through in vivo testing, FDA said
Topical Bioequivalence For Unlike Emulsions Should Be Tested In Vivo – FDA
Bioequivalence of topical dermatologic drugs in different emulsions that target the stratum corneum should be determined through in vivo testing, FDA said
DPK guidance to be withdrawn
FDA will withdraw draft guidance on dermatopharmacokinetics. "We are going to focus on a variety of other methods that make it possible for bioequivalence" for topical dermatologic products, Office of Pharmaceutical Science Acting Director Helen Winkle told the Generic Pharmaceutical Association's annual meeting in Coral Gables, Fla., April 10. "This is not to say that DPK is completely off the radar screen - we will continue to look at it - but we felt like we wanted to get the guidance out of publication." The agency has been considering alternatives following an unfavorable advisory committee meeting (1"The Pink Sheet" Dec. 17, 2001, p. 40)...